Daniel L. Hood, MD Medical Director, CompuNet Clinical Labs and Miami Valley Hospital
YORBA LINDA, Calif. December 04, 2017
Monoclonal Gammopathies (MG) are characterized by chromosomal aberration of B-cells or plasma cells resulting in benign or malignant proliferation of the affected clone. The product of such clone, a monoclonal protein, is an essential laboratory marker for the detection, identification and classification of MG and aid in diagnosing the associated conditions.
Currently there is no one test sensitive and specific enough to detect all Monoclonal Gammopathies. In some cases, multiple tests, including serum free light chain analysis, are required to uncover all plasma cell dyscrasias present in the patient.
Two electrophoresis techniques commonly used in clinical laboratory for typing MGs are Immunofixation and Immunotyping. During Immunofixation, samples are separated on a gel using zone electrophoresis and separation products are overlaid with specific antisera for detection. On capillary systems, MG can be characterized by mixing sample with Ig-specific antibodies followed by separation in an electrical field and observing resulting patterns for specific reduction of monoclonal peaks.
In this webinar, which is sponsored by Sebia, the speaker will discuss strategies for detecting Monoclonal Gammopathies. Participants will learn the principles of Immunotyping and Immunofixation, as well as review Immunotyping and Immunofixation results.
Dr. Daniel L. Hood, the Medical Director at CompuNet Clinical Labs and Miami Valley Hospital, will be the speaker for this event.
Hood attended The Ohio State University and received a Bachelor of Science in microbiology and immunology before graduating from Wright State University School of Medicine with his doctorate. Since 1997, he has been medical director of the clinical labs at Miami Valley Hospital and the CCL lab. During his career he has been on the boards of Miami Valley Hospital, Premier Health hospital system, Community Blood Center/Community Tissue Services, Ohio Society of Pathologists, and The Joint Restoration Foundation as well as serving as system pathology chair for Premier Health hospital system.
LabRoots will host the webinar December 5, 2017, beginning at 10:00 a.m. PST, 1:00 p.m. EST. to learn more about this event, discover the continuing education credits offered, or to register for free, click here.
Sebia is the world’s leading provider of clinical protein electrophoresis equipment and reagents, a technology used for in-vitro diagnostic (IVD) testing. Its systems analyze proteins in order to screen and monitor various diseases and conditions; primarily oncology (Multiple Myeloma), metabolic disorders such as Diabetes , Hemoglobinopathies, and rare pathologies.
LabRoots is the leading scientific social networking website, which provides daily scientific trending news, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.